Zimba Lotion contains Ozenoxacin 2% w/v, a topical non-fluorinated quinolone antibiotic indicated for the treatment of superficial bacterial skin infections, including impetigo caused by susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. Ozenoxacin exhibits potent bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, thereby preventing bacterial DNA replication and transcription. Zimba Lotion is formulated for topical application, allowing targeted antimicrobial action with minimal systemic absorption, reducing the risk of systemic side effects. Clinical studies have demonstrated its efficacy in resolving lesions and eradicating causative pathogens within a short treatment duration, typically 5 days. It is generally well tolerated, with adverse effects limited to mild local reactions such as erythema or pruritus at the application site. Zimba Lotion should be applied to clean, dry affected areas twice daily, avoiding contact with eyes and mucous membranes. It is contraindicated in patients with known hypersensitivity to Ozenoxacin or any formulation components. Caution is advised in pediatric patients under two months of age due to limited safety data. Zimba Lotion offers an effective topical therapeutic option for managing uncomplicated superficial bacterial skin infections, contributing to improved patient outcomes and reduced bacterial resistance development.